Disc Medicine Launches $220 Million Stock and Pre-Funded Warrant Offering
Reuters
Yesterday
<a href="https://laohu8.com/S/IRON">Disc Medicine</a> Launches $220 Million Stock and Pre-Funded Warrant Offering
Disc Medicine Inc. has announced the commencement of an underwritten public offering totaling $220 million in shares of its common stock and pre-funded warrants. Of this amount, $200 million in shares will be offered by Disc Medicine, while $20 million will be offered by AI DMI LLC, a selling stockholder. Additionally, the selling stockholder plans to grant underwriters a 30-day option to purchase up to an additional $33 million in shares. Disc Medicine intends to use the net proceeds to support the potential commercialization of bitopertin for erythropoietic protoporphyria $(EPP)$ and X-linked protoporphyria $(XLP)$, fund ongoing research and clinical development, and for general corporate purposes. The company will not receive proceeds from shares sold by the selling stockholder. Jefferies, Leerink Partners, Morgan Stanley, and Cantor are acting as joint book-running managers for the proposed offering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548281-en) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.